{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:34:39Z","timestamp":1790274879981,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Associazione Salute con Stile"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for patients with type 2 diabetes (T2D), in particular for older people. Newer glucose-lowering medications have generated some optimism on the possibility to influence the natural history of cardiorenal complications of T2D. This review summarizes work in the area of sodium\u2013glucose cotransporter 2 inhibitors (SGLT-2i) treatment and prevention of cardiorenal complications in patients with T2D (major adverse cardiovascular events, hospitalization for heart failure, kidney outcomes), with a particular emphasis on the effect of age, the role of primary versus secondary prevention and the possible extension of their cardiorenal benefits to the entire class of SGLT-2i.<\/jats:p>","DOI":"10.1186\/s12933-021-01213-w","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T10:49:21Z","timestamp":1610362161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Sodium\u2013glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9377-873X","authenticated-orcid":false,"given":"Dario","family":"Giugliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Scappaticcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"1213_CR1","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1001\/jama.2019.3471","volume":"321","author":"EW Gregg","year":"2019","unstructured":"Gregg EW, Hora I, Benoit SR. Resurgence in diabetes-related complications. JAMA. 2019;321:1867\u20138.","journal-title":"JAMA"},{"key":"1213_CR2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/dom.13629","volume":"21","author":"D Giugliano","year":"2019","unstructured":"Giugliano D, Meier JJ, Esposito K. Heart failure and type 2 diabetes: from cardiovascular outcome trials, with hope. Diabetes Obes Metab. 2019;21:1081\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"1213_CR3","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.2337\/dc20-0654","volume":"43","author":"JW Sacre","year":"2020","unstructured":"Sacre JW, Magliano DJ, Shaw JE. Incidence of hospitalization for heart failure relative to major atherosclerotic events in type 2 diabetes: a meta-analysis of cardiovascular outcomes trials. Diabetes Care. 2020;43:2614\u201323.","journal-title":"Diabetes Care"},{"key":"1213_CR4","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.2337\/dc18-0831","volume":"41","author":"YJ Cheng","year":"2018","unstructured":"Cheng YJ, Imperatore G, Geiss LS, et al. Trends and disparities in cardiovascular mortality among U.S. adults with and without sel freported diabetes mellitus, 1988\u20132015. Diabetes Care. 2018;41:2306\u201315.","journal-title":"Diabetes Care"},{"key":"1213_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633\u201344.","journal-title":"N Engl J Med"},{"key":"1213_CR6","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1161\/CIRCULATIONAHA.120.046783","volume":"142","author":"AK Wright","year":"2020","unstructured":"Wright AK, Suarez-Ortegon MF, Read SH, et al. Risk factor control and cardiovascular event risk in people with type 2 diabetes in primary and secondary prevention settings. Circulation. 2020;142:1925\u201336.","journal-title":"Circulation"},{"key":"1213_CR7","doi-asserted-by":"publisher","first-page":"6998","DOI":"10.1073\/pnas.1920391117","volume":"117","author":"NK Mehta","year":"2020","unstructured":"Mehta NK, Abrams LR, Myrskyl\u00e4 M. US life expectancy stalls due to cardiovascular disease, not drug deaths. Proc Natl Acad Sci USA. 2020;117:6998\u20137000.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1213_CR8","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium; 2019. http:\/\/www.diabetesatlas.org. Accessed 23 Nov 2020."},{"key":"1213_CR9","unstructured":"World Health Statistics 2019: Monitoring health for the SDGs. https:\/\/www.who.int\/gho\/publications\/world_health_statistics\/2019\/en\/. Accessed 23 Nov 2020."},{"key":"1213_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12020-017-1517-9","volume":"61","author":"D Giugliano","year":"2018","unstructured":"Giugliano D, Maiorino MI, Bellastella G, Esposito K. Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. Endocrine. 2018;61:23\u20137.","journal-title":"Endocrine"},{"key":"1213_CR11","doi-asserted-by":"publisher","first-page":"e012356","DOI":"10.1161\/JAHA.119.012356","volume":"8","author":"G Giugliano","year":"2019","unstructured":"Giugliano G, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta-analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. J Am Heart Assoc. 2019;8:e012356.","journal-title":"J Am Heart Assoc"},{"key":"1213_CR12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/dom.13581","volume":"21","author":"Y Barer","year":"2019","unstructured":"Barer Y, Cohen O, Cukierman-Yaffe T. Effect of glycaemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21:732\u20135.","journal-title":"Diabetes Obes Metab"},{"key":"1213_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S2213-8587(16)30091-2","volume":"4","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi F, Davies MJ, Dhalwani NN, et al. Trends in hospital admissions for hypoglycaemia in England: a retrospective, observational study. Lancet Diabetes Endocrinol. 2016;4:677\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1213_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1001\/jamainternmed.2014.7345","volume":"175","author":"KJ Lipska","year":"2015","unstructured":"Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Int Med. 2015;175:356\u201362.","journal-title":"JAMA Int Med"},{"key":"1213_CR15","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1177\/0003319715623400","volume":"67","author":"SW Yang","year":"2016","unstructured":"Yang SW, Park KH, Zhou YJ. The impact of hypoglycemia on the cardiovascular system: Physiology and pathophysiology. Angiology. 2016;67:802\u20139.","journal-title":"Angiology"},{"key":"1213_CR16","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","volume":"380","author":"CS Fox","year":"2012","unstructured":"Fox CS, Matsushita K, Woodward M, et al. Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662\u201373.","journal-title":"Lancet"},{"key":"1213_CR17","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.2337\/dc18-S010","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 10. Microvascular complications and foot care: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S105\u201318.","journal-title":"Diabetes Care"},{"key":"1213_CR18","doi-asserted-by":"publisher","first-page":"6.1","DOI":"10.1146\/annurev-med-042017-094221","volume":"70","author":"CK Kramer","year":"2019","unstructured":"Kramer CK, Zinman B. Sodium\u2013glucose cotransporter-2 (SGLT-2) inhibitors and the treatment of type 2 diabetes. Annu Rev Med. 2019;70:6.1-6.12.","journal-title":"Annu Rev Med"},{"key":"1213_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12933-019-0899-9","volume":"18","author":"D Giugliano","year":"2019","unstructured":"Giugliano D, Esposito K. Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Cardiovasc Diabetol. 2019;18:94.","journal-title":"Cardiovasc Diabetol"},{"issue":"Supplement 1","key":"1213_CR20","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.2337\/dc20-S012","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. Older adults: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Supplement 1):S152\u201362.","journal-title":"Diabetes Care"},{"key":"1213_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/dme.12651","volume":"32","author":"I Krass","year":"2015","unstructured":"Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. Diabet Med. 2015;32:725\u201337.","journal-title":"Diabet Med"},{"key":"1213_CR22","doi-asserted-by":"publisher","first-page":"e000512","DOI":"10.1136\/bmjdrc-2018-000512","volume":"6","author":"J Gordon","year":"2018","unstructured":"Gordon J, McEwan P, Idris I, Evans M, Puelles J. Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Res Care. 2018;6:e000512.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1213_CR23","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.2337\/dc16-1974","volume":"40","author":"SV Edelman","year":"2017","unstructured":"Edelman SV, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care. 2017;40:1469\u201378.","journal-title":"Diabetes Care"},{"key":"1213_CR24","doi-asserted-by":"crossref","unstructured":"Giugliano D, Maiorino MI, Bellastella G, Esposito K. Comment on Edelman and Polonsky. Type 2 Diabetes in the Real World: The elusive nature of glycemic control. Diabetes Care 2017;40:1425\u20131432. Diabetes Care. 2018;41:e17.","DOI":"10.2337\/dc17-1826"},{"key":"1213_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton CUH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17:83.","journal-title":"Cardiovasc Diabetol"},{"key":"1213_CR26","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2337\/dc16-2388","volume":"40","author":"KKW Olesen","year":"2017","unstructured":"Olesen KKW, Madsen M, Egholm G, et al. Patients with diabetes without significant angiographic coronary artery disease have the same risk of myocardial infarction as patients without diabetes in a real-world population receiving appropriate prophylactic treatment. Diabetes Care. 2017;40:1103\u201310.","journal-title":"Diabetes Care"},{"key":"1213_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u20139.","journal-title":"Lancet"},{"key":"1213_CR28","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/dom.14047","volume":"22","author":"D Giugliano","year":"2020","unstructured":"Giugliano D, Bellastella G, Longo M, et al. Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression. Diabetes Obes Metab. 2020;22:1397\u2013405.","journal-title":"Diabetes Obes Metab."},{"key":"1213_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, EMPA\u2013REG OUTCOME Investigators, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"1213_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, CANVAS Program Collaborative Group, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med."},{"key":"1213_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, DECLARE\u2013TIMI 58 Investigators, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1213_CR32","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, CREDENCE Trial Investigators, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1213_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12933-020-01010-x","volume":"19","author":"D Giugliano","year":"2020","unstructured":"Giugliano D, De Nicola L, Maiorino MI, et al. Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney. Cardiovasc Diabetol. 2020;19:35.","journal-title":"Cardiovasc Diabetol"},{"key":"1213_CR34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. NEJM. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2030186.","journal-title":"NEJM"},{"key":"1213_CR35","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425\u201335.","journal-title":"N Engl J Med"},{"key":"1213_CR36","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, DAPA-HF trial committees and investigators, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1213_CR37","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","volume":"142","author":"KF Docherty","year":"2020","unstructured":"Docherty KF, Jhund PS, Anand I, et al. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation. 2020;142:1623\u201332.","journal-title":"Circulation"},{"key":"1213_CR38","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"1213_CR39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Szarek MI, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. New Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2030183.","journal-title":"New Engl J Med"},{"key":"1213_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jrsm.1198","volume":"8","author":"D Langan","year":"2017","unstructured":"Langan D, Higgins JPT, Simmonds M. Comparative performance of heterogeneity variance estimators in meta-analysis: a review of simulation studies. Res Synth Methods. 2017;8:181\u201398.","journal-title":"Res Synth Methods"},{"key":"1213_CR41","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, for the DAPA-CKD Trial Committees and Investigators, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"1213_CR42","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.2337\/dc20-2173","volume":"43","author":"JA Shaw","year":"2020","unstructured":"Shaw JA, Cooper ME. Contemporary management of heart failure in patients with diabetes. Diabetes Care. 2020;43:2895\u2013903.","journal-title":"Diabetes Care"},{"key":"1213_CR43","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323:1353\u201368.","journal-title":"JAMA"},{"key":"1213_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.21395","author":"A Agarwal","year":"2020","unstructured":"Agarwal A, Yancy CW, Huffman MD. Improving care for heart failure with reduced ejection fraction\u2014a potential polypill-based strategy. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.21395.","journal-title":"JAMA"},{"key":"1213_CR45","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.5864","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Greene SJ, Zhang S, et al. Applicability of US Food and Drug Administration labeling for dapagliflozin to patients with heart failure with reduced ejection fraction in US clinical practice. The Get With the Guidelines-Heart Failure (GWTG-HF) registry. JAMA Cardiol. 2020. https:\/\/doi.org\/10.1001\/jamacardio.2020.5864.","journal-title":"JAMA Cardiol"},{"key":"1213_CR46","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Tamara Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1213_CR47","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE\u2013TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1213_CR48","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"1213_CR49","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a \u201cThrifty Substrate\u201d hypothesis. Diabetes Care. 2016;39:1108\u201314.","journal-title":"Diabetes Care"},{"key":"1213_CR50","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108\u201317.","journal-title":"Diabetologia"},{"key":"1213_CR51","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, et al. How Does Empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:356\u201363.","journal-title":"Diabetes Care"},{"key":"1213_CR52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","volume":"16","author":"V Vallon","year":"2020","unstructured":"Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020;16:317\u201336.","journal-title":"Nat Rev Nephrol"},{"key":"1213_CR53","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632\u201344.","journal-title":"JACC Basic Transl Sci"},{"key":"1213_CR54","doi-asserted-by":"publisher","first-page":"165770","DOI":"10.1016\/j.bbadis.2020.165770","volume":"1866","author":"I Andreadou","year":"2020","unstructured":"Andreadou I, Bell RB, B\u00f8tker HE, Zuurbier CJ. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165770.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1213_CR55","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Sindsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140:1463\u201376.","journal-title":"Circulation"},{"key":"1213_CR56","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1590\/1806-9282.65.1.70","volume":"65","author":"R Cintra","year":"2019","unstructured":"Cintra R, Moura FA, Carvalho LSF, et al. Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Rev Assoc Med Bras. 2019;65:70\u201386.","journal-title":"Rev Assoc Med Bras"},{"key":"1213_CR57","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/ggi.13149","volume":"18","author":"T Kambara","year":"2018","unstructured":"Kambara T, Shibata R, Osanai H, et al. Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus. Geriatr Gerontol Int. 2018;18:108\u201314.","journal-title":"Geriatr Gerontol Int"},{"key":"1213_CR58","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/ageing\/afz096","volume":"48","author":"P Monteiro","year":"2019","unstructured":"Monteiro P, Bergenstal RM, Toural E, et al. Efficacy and safety of empagliflozin in older patients inthe EMPA-REG OUTCOME\u00ae trial. Age Ageing. 2019;48:859\u201366.","journal-title":"Age Ageing"},{"key":"1213_CR59","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/dc19-1476","volume":"43","author":"A Cahn","year":"2020","unstructured":"Cahn A, Mosenzon O, Wiviott SD, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 Study. Diabetes Care. 2020;43:468\u201375.","journal-title":"Diabetes Care"},{"key":"1213_CR60","doi-asserted-by":"publisher","first-page":"108114","DOI":"10.1016\/j.diabres.2020.108114","volume":"162","author":"D Giugliano","year":"2020","unstructured":"Giugliano D, Longo M, Maiorino MI, et al. Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials. Diabetes Res Clin Pract. 2020;162:108114. https:\/\/doi.org\/10.1016\/j.diabres.2020.108114.","journal-title":"Diabetes Res Clin Pract"},{"key":"1213_CR61","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","volume":"141","author":"FA Martinez","year":"2020","unstructured":"Martinez FA, Serenelli M, Nicolau JC, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation. 2020;141:100\u201311.","journal-title":"Circulation"},{"issue":"suppl IV","key":"1213_CR62","first-page":"15","volume":"23","author":"CD Furberg","year":"2000","unstructured":"Furberg CD. Class effects and evidence based medicine. Clin Cardiol. 2000;23(suppl IV):15\u20139.","journal-title":"Clin Cardiol"},{"key":"1213_CR63","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, ESC Scientific Document Group, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255\u2013323.","journal-title":"Eur Heart J"},{"key":"1213_CR64","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/dom.13881","volume":"22","author":"D Giugliano","year":"2020","unstructured":"Giugliano D, Ceriello A, De Nicola L, Perrone-Filardi P, Cosentino F, Esposito K. Primary versus secondary cardiorenal prevention in type 2 diabetes: which newer anti-hyperglycaemic drug matters? Diabetes Obes Metab. 2020;22:149\u201357.","journal-title":"Diabetes Obes Metab"},{"key":"1213_CR65","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/dc16-0985","volume":"40","author":"KJ Lipska","year":"2017","unstructured":"Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006\u20132013. Diabetes Care. 2017;40:468\u201375.","journal-title":"Diabetes Care"},{"key":"1213_CR66","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14226","author":"BL Neuen","year":"2020","unstructured":"Neuen BL, Arnott C, Perkovic V, et al. Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes Obes Metab. 2020. https:\/\/doi.org\/10.1111\/dom.14226.","journal-title":"Diabetes Obes Metab"},{"key":"1213_CR67","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","volume":"72","author":"SR Das","year":"2018","unstructured":"Das SR, Everett BM, Birtcher KK, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol. 2018;72:3200\u201323.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 1","key":"1213_CR68","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc21-S010","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl. 1):S125\u2013S150.","journal-title":"Diabetes Care"},{"key":"1213_CR69","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","volume":"74","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74:1376\u2013414.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"1213_CR70","doi-asserted-by":"publisher","first-page":"i48","DOI":"10.1093\/ndt\/gfz252","volume":"35","author":"BL Neuen","year":"2020","unstructured":"Neuen BL, Jardine MJ, Perkovic V. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? Nephrol Dial Transplant. 2020;35(Suppl 1):i48\u201355.","journal-title":"Nephrol Dial Transplant"},{"key":"1213_CR71","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"PB Ryan","year":"2018","unstructured":"Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab. 2018;20:2585\u201397.","journal-title":"Diabetes Obes Metab"},{"key":"1213_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14189","author":"KI Birkeland","year":"2020","unstructured":"Birkeland KI, Bodegard J, Banerjee A, et al. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: a large multinational observational study. Diabetes Obes Metab. 2020. https:\/\/doi.org\/10.1111\/dom.14189.","journal-title":"Diabetes Obes Metab"},{"key":"1213_CR73","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/dom.13611","volume":"21","author":"D Fitchett","year":"2019","unstructured":"Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes Metab. 2019;21:34\u201342.","journal-title":"Diabetes Obes Metab"},{"key":"1213_CR74","doi-asserted-by":"publisher","first-page":"107639","DOI":"10.1016\/j.jdiacomp.2020.107639","volume":"34","author":"AH Abdelhafiz","year":"2020","unstructured":"Abdelhafiz AH, Sinclairbc AJ. Cardio-renal protection in older people with diabetes with frailty and medical comorbidities\u2014a focus on the new hypoglycaemic therapy. J Diabetes Compl. 2020;34:107639.","journal-title":"J Diabetes Compl"},{"key":"1213_CR75","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14159","author":"CY Huang","year":"2020","unstructured":"Huang CY, Lee JK. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51,713 individuals. Diabetes Obes Metab. 2020. https:\/\/doi.org\/10.1111\/dom.14159 (Online ahead of print).","journal-title":"Diabetes Obes Metab"},{"key":"1213_CR76","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1073","author":"M Suissa","year":"2020","unstructured":"Suissa M, Yin H, Yu OHY, Wong SM, Azoulay L. Sodium\u2013glucose cotransporter 2 inhibitors and the short-term risk of breast cancer among women with type 2 diabetes. Diabetes Care. 2020. https:\/\/doi.org\/10.2337\/dc20-1073 (Publish Ahead of Print).","journal-title":"Diabetes Care"},{"key":"1213_CR77","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12933-020-01154-w","volume":"19","author":"G Schernthaner","year":"2020","unstructured":"Schernthaner G, Shehadeh N, Ametov AS, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19:185.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01213-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-021-01213-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01213-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T12:43:26Z","timestamp":1610369006000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01213-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01213-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"5 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DG received honoraria for speaking at meetings from Novartis, Sanofi, Lilly, Astrazeneca, and NovoNordisk. K.E. received honoraria for speaking at meetings from Novartis, Sanofi-Aventis, Lilly, AstraZeneca, Boehringer Ingelheim, and NovoNordisk. No other potential conflict of interest relevant to this article was reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}